Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.55
VCEL's Cash-to-Debt is ranked lower than
75% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. VCEL: 1.55 )
Ranked among companies with meaningful Cash-to-Debt only.
VCEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.38  Med: 278.38 Max: No Debt
Current: 1.55
1.38
No Debt
Equity-to-Asset 0.42
VCEL's Equity-to-Asset is ranked lower than
76% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. VCEL: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
VCEL' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.22  Med: 0.89 Max: 0.98
Current: 0.42
-7.22
0.98
Debt-to-Equity 0.60
VCEL's Debt-to-Equity is ranked lower than
73% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 0.26 vs. VCEL: 0.60 )
Ranked among companies with meaningful Debt-to-Equity only.
VCEL' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.14  Med: 0.01 Max: 0.9
Current: 0.6
-0.14
0.9
Debt-to-EBITDA -0.47
VCEL's Debt-to-EBITDA is ranked lower than
99.99% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. VCEL: -0.47 )
Ranked among companies with meaningful Debt-to-EBITDA only.
VCEL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.58  Med: -0.02 Max: 0
Current: -0.47
-0.58
0
Piotroski F-Score: 4
Altman Z-Score: -5.89
Beneish M-Score: -2.08
WACC vs ROIC
30.78%
-234.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -38.64
VCEL's Operating Margin % is ranked higher than
59% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -105.96 vs. VCEL: -38.64 )
Ranked among companies with meaningful Operating Margin % only.
VCEL' s Operating Margin % Range Over the Past 10 Years
Min: -161333.33  Med: -6474.51 Max: -32.58
Current: -38.64
-161333.33
-32.58
Net Margin % -41.63
VCEL's Net Margin % is ranked higher than
57% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -92.13 vs. VCEL: -41.63 )
Ranked among companies with meaningful Net Margin % only.
VCEL' s Net Margin % Range Over the Past 10 Years
Min: -140352.38  Med: -6309.22 Max: -31.93
Current: -41.63
-140352.38
-31.93
ROE % -156.46
VCEL's ROE % is ranked lower than
85% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: -39.05 vs. VCEL: -156.46 )
Ranked among companies with meaningful ROE % only.
VCEL' s ROE % Range Over the Past 10 Years
Min: -816.1  Med: -90.49 Max: -49.85
Current: -156.46
-816.1
-49.85
ROA % -61.26
VCEL's ROA % is ranked lower than
68% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. VCEL: -61.26 )
Ranked among companies with meaningful ROA % only.
VCEL' s ROA % Range Over the Past 10 Years
Min: -257.22  Med: -70.13 Max: -39.91
Current: -61.26
-257.22
-39.91
ROC (Joel Greenblatt) % -217.46
VCEL's ROC (Joel Greenblatt) % is ranked higher than
57% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. VCEL: -217.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VCEL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2141.13  Med: -1049.32 Max: -210.99
Current: -217.46
-2141.13
-210.99
3-Year Revenue Growth Rate 632.20
VCEL's 3-Year Revenue Growth Rate is ranked higher than
100% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. VCEL: 632.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VCEL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -76  Med: -26.95 Max: 632.2
Current: 632.2
-76
632.2
3-Year EBITDA Growth Rate -46.90
VCEL's 3-Year EBITDA Growth Rate is ranked lower than
93% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. VCEL: -46.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VCEL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.6  Med: -20.65 Max: 6.4
Current: -46.9
-64.6
6.4
3-Year EPS without NRI Growth Rate -44.60
VCEL's 3-Year EPS without NRI Growth Rate is ranked lower than
90% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. VCEL: -44.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VCEL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.9  Med: -18.65 Max: 7.2
Current: -44.6
-60.9
7.2
GuruFocus has detected 7 Warning Signs with Vericel Corp VCEL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VCEL's 30-Y Financials

Financials (Next Earnings Date: 2018-03-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

VCEL Guru Trades in Q1 2017

Jim Simons 81,600 sh (-81.32%)
» More
Q2 2017

VCEL Guru Trades in Q2 2017

Jim Simons Sold Out
» More
Q3 2017

VCEL Guru Trades in Q3 2017

Jim Simons 250,192 sh (New)
» More
Q4 2017

VCEL Guru Trades in Q4 2017

Jim Simons 145,400 sh (-41.88%)
» More
» Details

Insider Trades

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:NERV, NAS:FWP, NAS:CASI, TSXV:COB.U, TSX:VBV, TSX:NEPT, NAS:VTL, OCSE:ORPHA, XKRX:115180, NAS:CASC, NAS:KIN, XTER:B8F, NAS:FOMX, OSTO:BIOA B, NAS:NBRV, XKRX:060590, TSX:RVX, ASX:PNV, XSWX:EVE, ASX:MVF » details
Traded in other countries:ATQP.Germany,
Headquarter Location:USA
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company. The Company operates in one reportable segment: the research, manufacture, and distribution of patient-specific, used in the treatment of specific diseases.

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development, and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products and the goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs. The Company operates in one reportable segment: the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Ratios

vs
industry
vs
history
PB Ratio 14.60
VCEL's PB Ratio is ranked lower than
86% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. VCEL: 14.60 )
Ranked among companies with meaningful PB Ratio only.
VCEL' s PB Ratio Range Over the Past 10 Years
Min: 1.21  Med: 3.9 Max: 40.69
Current: 14.6
1.21
40.69
PS Ratio 3.64
VCEL's PS Ratio is ranked higher than
77% of the 731 Companies
in the Global Biotechnology industry.

( Industry Median: 11.11 vs. VCEL: 3.64 )
Ranked among companies with meaningful PS Ratio only.
VCEL' s PS Ratio Range Over the Past 10 Years
Min: 0.85  Med: 194.2 Max: 35000
Current: 3.64
0.85
35000
EV-to-EBIT -10.52
VCEL's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.83 vs. VCEL: -10.52 )
Ranked among companies with meaningful EV-to-EBIT only.
VCEL' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.15  Med: -3.1 Max: -0.3
Current: -10.52
-11.15
-0.3
EV-to-EBITDA -11.38
VCEL's EV-to-EBITDA is ranked lower than
99.99% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 20.69 vs. VCEL: -11.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
VCEL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.3  Med: -3.2 Max: -0.3
Current: -11.38
-12.3
-0.3
EV-to-Revenue 4.19
VCEL's EV-to-Revenue is ranked higher than
76% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 12.21 vs. VCEL: 4.19 )
Ranked among companies with meaningful EV-to-Revenue only.
VCEL' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 137.9 Max: 27402.5
Current: 4.19
1.3
27402.5
Current Ratio 2.50
VCEL's Current Ratio is ranked lower than
68% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. VCEL: 2.50 )
Ranked among companies with meaningful Current Ratio only.
VCEL' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 8.07 Max: 45.43
Current: 2.5
0.3
45.43
Quick Ratio 2.22
VCEL's Quick Ratio is ranked lower than
67% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. VCEL: 2.22 )
Ranked among companies with meaningful Quick Ratio only.
VCEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.3  Med: 7.9 Max: 45.15
Current: 2.22
0.3
45.15
Days Inventory 45.09
VCEL's Days Inventory is ranked higher than
79% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. VCEL: 45.09 )
Ranked among companies with meaningful Days Inventory only.
VCEL' s Days Inventory Range Over the Past 10 Years
Min: 1.63  Med: 22.75 Max: 56.64
Current: 45.09
1.63
56.64
Days Sales Outstanding 98.64
VCEL's Days Sales Outstanding is ranked lower than
73% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 65.03 vs. VCEL: 98.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
VCEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.59  Med: 103.82 Max: 182.5
Current: 98.64
12.59
182.5
Days Payable 73.75
VCEL's Days Payable is ranked higher than
56% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 59.19 vs. VCEL: 73.75 )
Ranked among companies with meaningful Days Payable only.
VCEL' s Days Payable Range Over the Past 10 Years
Min: 73.75  Med: 6695.86 Max: 244185
Current: 73.75
73.75
244185

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -75.90
VCEL's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. VCEL: -75.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VCEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -131  Med: -30.55 Max: -9.1
Current: -75.9
-131
-9.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 18.92
VCEL's Price-to-Net-Current-Asset-Value is ranked lower than
80% of the 694 Companies
in the Global Biotechnology industry.

( Industry Median: 7.04 vs. VCEL: 18.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VCEL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.36  Med: 5.28 Max: 540.54
Current: 18.92
1.36
540.54
Price-to-Tangible-Book 14.58
VCEL's Price-to-Tangible-Book is ranked lower than
79% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 5.30 vs. VCEL: 14.58 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VCEL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.34  Med: 5.12 Max: 60
Current: 14.58
1.34
60
Price-to-Median-PS-Value 0.02
VCEL's Price-to-Median-PS-Value is ranked higher than
100% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. VCEL: 0.02 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VCEL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.48 Max: 171.58
Current: 0.02
0.01
171.58
Earnings Yield (Greenblatt) % -9.52
VCEL's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. VCEL: -9.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VCEL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -313.6  Med: -32.7 Max: -8.98
Current: -9.52
-313.6
-8.98

More Statistics

Revenue (TTM) (Mil) $57.10
EPS (TTM) $ -0.88
Beta4.73
Short Percentage of Float3.09%
52-Week Range $2.35 - 8.25
Shares Outstanding (Mil)34.91

Analyst Estimate

Dec17
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.23
EPS without NRI ($) -0.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}